« Back
Home /
Infliximab (anti-TNF-alpha)

Infliximab (anti-TNF-alpha)

Manufacturer	Selleckchem
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes By Cell Type Cell Biology Obesity Cell Culture Cytokines Cell Status Necrosis Apoptosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	1 mg x 5
Item no.	A2019-5
Targets	TNF
CASRN	170277-31-3
eClass 6.1	30220300
eClass 9.0	32160605
Available
Description	Infliximab (anti-TNF-alpha) (Remicade, Remsima, Inflectra) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha, and inhibits or prevents the effective binding of TNF-alpha with its receptors. MW=144.2 kDa.
Pathway	Apoptosis
Small Target	TNF-alpha

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg x 5

available

Delivery expected until 5/16/2024